Physician profile
Anis U Ansari
NPI 1487602553
$1,188.52
in general payments reported to CMS, 2019-2025
26 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $116 · 2021: $31.95 · 2022: $16.71 · 2023: $230 · 2024: $341 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $138.49 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $116.24 | 2019-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $106.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.24 | 2020-2025 | Breztri, Farxiga |
| Amgen INC. | $80.80 | 2023-2025 | Evenity, Tavneos, Prolia |
| Janssen Pharmaceuticals, INC | $73.49 | 2019-2020 | |
| Lilly USA, LLC | $69.94 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $52.19 | 2019-2025 | |
| Mylan Specialty L.P. | $48.57 | 2019-2024 | Yupelri |
| Daiichi Sankyo INC. | $41.65 | 2024 | Injectafer |
| Mallinckrodt Hospital Products INC. | $41.19 | 2023 | Acthar |
| Teva Pharmaceuticals USA, INC. | $36.34 | 2024-2025 | Austedo Xr, Austedo Xr |
| Opko Pharmaceuticals, LLC | $33.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.55 | 2019-2021 | |
| Ardelyx, INC. | $29.08 | 2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $27.68 | 2019 | |
| Dexcom, INC. | $19.18 | 2024 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $18.89 | 2025 | Onivyde |
| E.R. Squibb & Sons, L.L.C. | $18.21 | 2020 | |
| Calliditas Therapeutics US INC. | $17.61 | 2023 | Tarpeyo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.38 | 2025 | Caplyta |
| Genentech USA, INC. | $17.01 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.71 | 2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $14.88 | 2025 | Shingrix |
| Alexion Pharmaceuticals, INC. | $14.76 | 2023 | Ultomiris |
| Pfizer INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anis Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.